Companies in race to bring tardive dyskinesia therapy to market
By Brian Orelli
Monday, August 18, 2014
Nearly 60 years after tardive dyskinesia (TD) was recognized as a disease, patients may soon have a drug approved to treat their involuntary movements.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.